iCAD Launches ProFound Cloud at JFR 2024
iCAD, Inc. (NASDAQ: ICAD), a pioneering force in AI-driven cancer detection solutions, recently showcased its latest advancements at the Journées Francophones de Radiologie (JFR) 2024 Meeting in Paris. Celebrated for its commitment to improving patient outcomes, iCAD introduced its ProFound Cloud, a secure and scalable platform empowering healthcare providers globally with advanced AI technologies.
Rapid Adoption and Global Availability
With impressive performance metrics under its belt, ProFound Cloud has already processed nearly 100,000 cases in just two quarters since its U.S. launch. This remarkable achievement underscores the rapid adoption of this innovative AI solution, which promises processing speeds exceeding traditional on-premises systems by over 50%. Thanks to strategic partnerships and regulatory approvals, the ProFound Cloud's global availability is set to expand further.
Strategic Partnerships and Regulatory Milestones
iCAD's recent advancements have been bolstered by enriching collaborations with distribution partners in several key countries, including the Dominican Republic, France, Spain, Turkey, and the United Arab Emirates. Collaborations with healthcare technology innovators such as Tamer and deepc further amplify the reach of iCAD’s ProFound AI solutions across various health systems.
In its stride for international growth, iCAD has also secured crucial regulatory clearances for its ProFound AI platform in South Africa and the United Arab Emirates. This not only reflects the company’s commitment to global healthcare enhancement but also positions iCAD as a critical player in the international medical imaging landscape.
The ProFound Cloud Platform
Built upon the robust framework of Google's Cloud Platform, ProFound Cloud offers an extraordinary blend of scalability, security, and affordability. It provides healthcare providers access to cutting-edge AI technologies designed to improve breast health diagnostics. With ongoing updates and enhancements, the platform is adaptable for institutions of all sizes, paving the way for improved operational efficiencies.
Expert Insights at JFR 2024
As part of the JFR 2024 program, iCAD hosted an insightful AI Symposium featuring Prof. Bruno Boyer from the Centre for Medical Imaging in Italy. The session titled "Contribution of iCAD's Artificial Intelligence Solutions for Better Breast Cancer Screening: Detection, Density, and Risk" highlighted how iCAD’s ProFound AI technologies are setting the stage for advancements in breast cancer screening. Prof. Boyer presented a summary of current clinical studies, emphasizing the progressive role of AI in enhancing detection rates and assessing risk.
Engagement Opportunities at JFR 2024
Guests attending the JFR 2024 event were encouraged to visit iCAD at booth #226A. There, they could engage in live demonstrations of iCAD's revolutionary AI-powered technologies and explore the company’s ongoing dedication to transforming breast health through innovative solutions. Attendees who wished to connect with the iCAD team or arrange virtual demonstrations were directed to the company's event page for further information.
About iCAD, Inc.
Headquartered in Nashua, N.H., iCAD, Inc. (NASDAQ: ICAD) is dedicated to the mission of eliminating cancer with extensive AI-driven detection solutions. The flagship ProFound Breast Health Suite provides comprehensive analysis for breast cancer detection, density assessment, and risk evaluation. With a presence in over 50 countries and spanning more than 40 million mammograms read—30% of which are tomosynthesis—iCAD stands at the forefront of breast health technology and innovations aimed at improving patient outcomes globally.
Frequently Asked Questions
What is ProFound Cloud?
ProFound Cloud is an AI-powered SaaS platform launched by iCAD that provides healthcare providers with advanced tools for cancer detection and diagnostics.
How has ProFound Cloud performed since its launch?
Since its launch, ProFound Cloud has processed nearly 100,000 cases, highlighting its rapid adoption and effectiveness in clinical settings.
What markets is iCAD expanding into?
iCAD is expanding its presence into international markets including the Dominican Republic, France, Spain, Turkey, South Africa, and the United Arab Emirates.
Who led the AI Symposium at JFR 2024?
Prof. Bruno Boyer from the Centre for Medical Imaging in Italy led the AI Symposium discussing the impact of iCAD's technologies on breast cancer screening.
What is the focus of iCAD's technology?
iCAD focuses on delivering AI-driven solutions aimed at improving the accuracy and efficiency of cancer detection, particularly in breast health diagnostics.